This study demonstrated IsoLG-modified apoAI is increased in patients and animals with kidney disease and that IsoLG-apoAI contributes to renal disease progression by upregulating inflammatory cytokines, increasing oxidative stress in lymphatic endothelial cells, and compromizing lymphatic vessel pumping dynamics. The gene discussed is APOA1; the disease is kidney disorder.